Standout Papers

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expr... 2023 2026 2024195
  1. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study (2023)
    Ursula A. Matulonis, Domenica Lorusso et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 66 standout
Sub-graph 1 of 22

Citing Papers

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
2024 Standout
Bispecific antibody drug conjugates: Making 1+1>2
2024 Standout
8 intermediate papers

Works of Brooke Esteves being referenced

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
2023 Standout
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.
2021
and 5 more

Author Peers

Author Last Decade Papers Cites
Brooke Esteves 282 296 170 307 30 629
Graham Temple 429 438 130 287 16 710
George Au‐Yeung 113 432 161 284 40 663
Catherine J. Kennedy 173 181 81 231 24 542
Sofia Genta 136 417 109 278 36 708
Evangelos Bournakis 159 265 83 267 34 610
Stefano Sioletic 276 236 54 208 27 702
Even Birkeland 93 165 124 293 27 640
Anna Berg 98 159 178 283 21 657
Frederik Holst 120 245 85 353 23 718
Virpi Rantanen 117 406 70 279 33 728

All Works

Loading papers...

Rankless by CCL
2026